- Browse by Subject
Browsing by Subject "FDG"
Now showing 1 - 4 of 4
Results Per Page
Sort Options
Item Normal Patterns and Pitfalls of FDG Uptake in the Head and Neck(Elsevier, 2019) Gray, Benjamin R.; Koontz, Nicholas A.; Radiology and Imaging Sciences, School of MedicineIn order to avoid misdiagnoses, medical imagers should be familiar with the normal patterns and distribution of fluorodeoxyglucose (FDG) activity within the head and neck, as well as the pathophysiology and imaging-findings of common diagnostic pitfalls related to incidental FDG-avid lesions. The purpose of this article is to provide an image-rich review of the normal patterns of FDG uptake in the head and neck, help differentiate benign from malignant incidentally found FDG-avid foci, and detail important “don't miss” hypometabolic head and neck lesions on positron emission tomography/computed tomography and positron emission tomography/magnetic resonance imaging.Item Squamous Cell Carcinoma: PET/CT and PET/MRI of the Pretreatment and Post-Treatment Neck(Elsevier, 2019) Traylor, Katie S.; Koontz, Nicholas; Mosier, Kristine; Radiology and Imaging Sciences, School of MedicineThe incidence of head and neck cancer continues to rise annually, most commonly squamous cell carcinoma (SCCa). Advances in imaging techniques have improved diagnostic accuracy with important ramifications for initial staging and post-treatment surveillance. FDG-PET/CT and, more recently, FDG-PET/MRI have revolutionized the staging and surveillance of head and neck SCCa. We detail the diagnostic role of FDG-PET/CT and FDG-PET/MRI of SCCa at the different head and neck subsites, highlighting their role in identifying the primary tumor extent, regional nodal metastases, and distant metastatic disease in the pretreatment and post-treatment setting, as well as implications for staging, treatment, and prognosis.Item Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease(Elsevier, 2018-09-27) Joseph-Mathurin, Nelly; Su, Yi; Blazey, Tyler M.; Jasielec, Mateusz; Vlassenko, Andrei; Friedrichsen, Karl; Gordon, Brian A.; Hornbeck, Russ C.; Cash, Lisa; Ances, Beau M.; Veale, Thomas; Cash, David M.; Brickman, Adam M.; Buckles, Virginia; Cairns, Nigel J.; Cruchaga, Carlos; Goate, Alison; Jack, Clifford R., Jr.; Karch, Celeste; Klunk, William; Koeppe, Robert A.; Marcus, Daniel S.; Mayeux, Richard; McDade, Eric; Noble, James M.; Ringman, John; Saykin, Andrew J.; Thompson, Paul M.; Xiong, Chengjie; Morris, John C.; Bateman, Randall J.; Benzinger, Tammie L. S.; Dominantly Inherited Alzheimer Network; Radiology and Imaging Sciences, School of MedicineIntroduction: 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is commonly used to estimate neuronal injury in Alzheimer's disease (AD). Here, we evaluate the utility of dynamic PET measures of perfusion using 11C-Pittsburgh compound B (PiB) to estimate neuronal injury in comparison to FDG PET. Methods: FDG, early frames of PiB images, and relative PiB delivery rate constants (PiB-R1) were obtained from 110 participants from the Dominantly Inherited Alzheimer Network. Voxelwise, regional cross-sectional, and longitudinal analyses were done to evaluate the correlation between images and estimate the relationship of the imaging biomarkers with estimated time to disease progression based on family history. Results: Metabolism and perfusion images were spatially correlated. Regional PiB-R1 values and FDG, but not early frames of PiB images, significantly decreased in the mutation carriers with estimated year to onset and with increasing dementia severity. Discussion: Hypometabolism estimated by PiB-R1 may provide a measure of brain perfusion without increasing radiation exposure.Item Whole body metabolic tumor volume is a prognostic marker in patients with newly diagnosed stage 3B non-small cell lung cancer, confirmed with external validation(SpringerOpen, 2017) Dashevsky, Brittany Z.; Zhang, Chenpeng; Yan, Li; Yuan, Cindy; Xiong, Lingyun; Liu, Yongmei; Liu, Haiyan; Spring Kong, Feng-Ming; Pu, Yonglin; Medical and Molecular Genetics, School of MedicinePurpose: TNM Stage 3B encompasses a wide range of primary tumor and nodal metastatic tumor burden. This study aimed to evaluate the prognostic value of quantitative FDG PET/CT parameters in patients with newly diagnosed Stage 3B Non-Small Cell Lung Cancer (NSCLC). Materials and Methods: Institutional review board approved retrospective study identified patients diagnosed with Stage 3B NSCLC (8th edition TNM classification) on baseline FDG PET/CT at two medical centers (Medical centers A and B), between Feb 2004 and Dec 2014. Patients were excluded if they had prior NSCLC treatment or recent diagnosis of a second primary cancer. Quantitative FDG PET/CT parameters including whole body metabolic tumor volume (MTVwb), total lesion glycolysis (TLGwb), and maximum standardized uptake value (SUVmaxwb) were measured from baseline PET/CT using Edge method with Mimvista software. The primary endpoint was overall survival (OS). Cox proportional hazard regression and Kaplan-Meier overall survival analyses were used to test for an association between OS and quantitative FDG PET/CT parameters. The distributions of MTVwb, TLGwb, SUVmaxwb were skewed, so a natural logarithm transformation was applied and the transformed variables [(ln(MTVwb), ln(TLGwb), and ln(SUVmaxwb)] were used in the analysis. Results: The training set included 110 patients from center A with Stage 3B NSCLC. 78.2% of patients expired during follow-up. Median OS was 14 months. 1-year, 2-year, and 5-year OS was 56.5%, 34.6% and 13.9%, respectively. Univariate Cox regression analysis showed no significant difference in OS on the basis of age, gender, histology, ln(TLGwb), or ln(SUVmaxwb). ln(MTVwb) was positively associated with OS [hazard ratio (HR) of 1.23, p = 0.037]. This association persisted on multivariate Cox regression analysis (HR 1.28, p = 0.043), with adjustments for age, gender, treatment and tumor histology. External validation with 44 patients from center B confirmed increasing MTVwb was associated significantly worse OS. An MTVwb cut-off point of 85.6 mL significantly stratified Stage 3B NSCLC patient prognosis. Conclusion: MTVwb is a prognostic marker for OS in patients with Stage 3B NSCLC, independent of age, gender, treatment, and tumor histology.